Evidence map›Paper›PMID 41557039›Full record

ArticleBreast cancer research and treatment2026

Real-world outcomes of reduced-dose versus standard-dose antibody drug conjugates in metastatic breast cancer: a retrospective cohort study.

Nickolas Stabellini, Jasskiran Kaur, Cynthia Owusu, Bahar Moftakhar, Takae Mizukami, Sonia D de Oliveira, Alberto J Montero

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Nickolas StabelliniDepartment of Hematology-Oncology, University Hospitals Seidman Cancer Center, 11100 Euclid Ave, Cleveland, OH, 44106, USA. Nickolas.Stabellini@UHHospitals.org.
Jasskiran KaurDepartment of Hematology-Oncology, University Hospitals Seidman Cancer Center, 11100 Euclid Ave, Cleveland, OH, 44106, USA.
Cynthia OwusuDepartment of Hematology-Oncology, University Hospitals Seidman Cancer Center, 11100 Euclid Ave, Cleveland, OH, 44106, USA.
Bahar MoftakharDepartment of Hematology-Oncology, University Hospitals Seidman Cancer Center, 11100 Euclid Ave, Cleveland, OH, 44106, USA.
Takae MizukamiDepartment of Hematology-Oncology, University Hospitals Seidman Cancer Center, 11100 Euclid Ave, Cleveland, OH, 44106, USA.
Sonia D de OliveiraDepartment of Hematology-Oncology, University Hospitals Seidman Cancer Center, 11100 Euclid Ave, Cleveland, OH, 44106, USA.
Alberto J MonteroDepartment of Hematology-Oncology, University Hospitals Seidman Cancer Center, 11100 Euclid Ave, Cleveland, OH, 44106, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate whether reduced doses (RD) of trastuzumab deruxtecan (T-DXd) or sacituzumab govitecan (SG) provide similar outcomes to the approved standard doses (SD) in metastatic breast cancer (mBC).

methodsThis retrospective cohort included mBC patients receiving at least one cycle of SG (April 2021-May 2024) or T-DXd (February 2020-December 2024). Primary outcomes were progression-free survival (PFS) and overall survival (OS). Kaplan-Meier curves and Log-Rank tests estimated and compared PFS and OS from treatment initiation. Subgroup analyses were performed by HER2 and hormone receptor status.

results48 patients received SG (24 RD vs. 24 SD) and 66 received T-DXd (29 RD vs. 37 SD). Median PFS for SG was 3 months in both SD (95% CI, 2-10) and RD (95% CI, 2-8; p = 0.8). Median OS for SG was 10 months (95% CI, 7-13) for SD and 11 months (95% CI, 5-30; p = 0.4) for RD. For T-DXd, median PFS was 10.4 months for SD (95% CI, 7.0-14.5) and 11.2 months for RD (95% CI, 5.4-31.1; p = 0.8), while median OS was 18.3 months (95% CI, 13.9-NA) for SD and 28.1 months (95% CI, 18.2-NA; p = 0.9) for RD. Overall response rates were similar between patients receiving RD and SD SG or T-DXd.

conclusionsThis real-world data suggest RD of SG or T-DXd achieve outcomes comparable to SD, supporting prospective evaluation of lower-dose regimens.

Indexed as

Antibodies, Monoclonal, HumanizedBreast NeoplasmsCamptothecinImmunoconjugatesTrastuzumabAdultAgedAntineoplastic Agents, ImmunologicalErb-b2 Receptor Tyrosine KinasesFemaleHumansMiddle AgedNeoplasm MetastasisProgression-Free SurvivalRetrospective StudiesTreatment OutcomeAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalCamptothecinErb-b2 Receptor Tyrosine KinasesImmunoconjugatessacituzumab govitecanTrastuzumabAntibody–drug conjugateMetastatic breast cancerReduced doseSacituzumab govitecanSurvivalTrastuzumab deruxtecan

Identifiers

PMID41557039
PMCPMC12819492

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.